Clinical trials
Terminated Carcinoma, Renal Cell trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
278 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 5 |
| 2004 | 6 |
| 2005 | 9 |
| 2006 | 10 |
| 2007 | 12 |
| 2008 | 19 |
| 2009 | 9 |
| 2010 | 17 |
| 2011 | 11 |
| 2012 | 15 |
| 2013 | 9 |
| 2014 | 10 |
| 2015 | 14 |
| 2016 | 13 |
| 2017 | 15 |
| 2018 | 16 |
| 2019 | 15 |
| 2020 | 23 |
| 2021 | 13 |
| 2022 | 8 |
| 2023 | 12 |
| 2024 | 8 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 278 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 19 |
| Pfizer | 14 |
| M.D. Anderson Cancer Center | 9 |
| Novartis Pharmaceuticals | 7 |
| Bayer | 5 |
| Hoffmann-La Roche | 4 |
| University of Chicago | 4 |
| Agenus Inc. | 3 |
| Celldex Therapeutics | 3 |
| Duke University | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Renal Cell | 278 |
| Kidney Neoplasms | 61 |
| Melanoma | 57 |
| Carcinoma, Non-Small-Cell Lung | 54 |
| Neoplasm Metastasis | 40 |
| Neoplasms | 30 |
| Ovarian Neoplasms | 25 |
| Colorectal Neoplasms | 24 |
| Squamous Cell Carcinoma of Head and Neck | 22 |
| Triple Negative Breast Neoplasms | 21 |
Trials
Showing 51 to 75 of 278. Each trial links to its page on Pharma Observatory.
178 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.